Rohit Singh,Krina Patel,Haze Xu et al.
Rohit Singh et al.
Assessing cardiac risk prior to initiating breast cancer treatment, monitoring cardiac function during treatment, and implementing appropriate follow-up strategies are essential components of managing cardiotoxicity in breast cancer patient...
Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine [0.03%]
精准医学背景下阴茎肿瘤分子病理新进展及其临床应用前景展望
Laura Elst,Kaat Vandermaesen,Maarten Albersen
Laura Elst
Penile cancer is a rare but aggressive malignancy, characterized by early lymphatic spread which is the most critical prognostic factor. Treatment options for patients with locally advanced and metastatic disease are limited, primarily rely...
Oral Budesonide in Oncology: A Novel Approach to Managing Gastrointestinal Immune-Related Adverse Events [0.03%]
口腔布地奈德在肿瘤学中的应用：管理胃肠免疫相关不良事件的新方法
Piotr T Wysocki,Jarosław Reguła
Piotr T Wysocki
Budesonide is a potent topical glucocorticosteroid with limited systemic activity owing to its extensive hepatic first-pass metabolism following oral administration. Its efficacy and safety have been well-established in gastroenterology, pa...
Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies [0.03%]
全面评估在血液干细胞移植和细胞疗法老年患者中的作用
Lawrence Cheng Kiat Ng,Rachel Qiao Ming Ng,Joseph DiTursi et al.
Lawrence Cheng Kiat Ng et al.
Hematological malignancies are common among older adults, a group that faces unique challenges in treatment. While hematopoietic stem cell transplantation and CAR-T therapy offer promising, potentially curative and durable treatment options...
Therapeutic Challenges in the Management of Serous Endometrial Intraepithelial Carcinoma (SEIC) [0.03%]
透明细胞内皮elial癌的治疗挑战
Emily Hicks,Akash Shah,Robert V Higgins
Emily Hicks
Serous endometrial intraepithelial carcinoma (SEIC) is an aggressive precursor and a similar biology to uterine serous carcinoma (USC). Patients diagnosed with SEIC should undergo surgical staging that includes total hysterectomy with bilat...
Review of Bone Metastasis in Gynecologic Malignancies: Evaluation and Treatment [0.03%]
妇科恶性肿瘤骨转移的评估与治疗进展——回顾性研究
Miller Singleton,Kevin Tam,Ashley Weiner et al.
Miller Singleton et al.
Metastatic bone disease (MBD) is a significant source of morbidity and mortality in cancer patients with solid tumors, including those with gynecologic malignancies. Infiltration of tumor cells within the bone microenvironment disrupts bone...
Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma [0.03%]
follicular淋巴瘤的个性化治疗及预后因素的研究进展
Shijia Cheng,Yanyan Liu
Shijia Cheng
Follicular lymphoma is the most prevalent form of indolent B-cell lymphoma, characterized by gradual disease progression and potential survival over several decades. Although the overall prognosis is typically favorable, some patients remai...
Correction to: Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies [0.03%]
校正： Succinate脱氢酶不足的胃肠道间质瘤系统治疗最近取得的进展
Demitrios Dedousis,Elyse Gadra,Joseph Van Galen et al.
Demitrios Dedousis et al.
Published Erratum
Current treatment options in oncology. 2025 Apr 1. DOI:10.1007/s11864-025-01315-7 2025
Novel Estrogen Receptor - Targeted Therapies in Hormone-Receptor Positive Breast Cancer [0.03%]
激素受体阳性乳腺癌中的新型雌激素受体靶向治疗
Nina E Neill,Lauren A Mauro,Angela Pennisi
Nina E Neill
Endocrine therapy is the backbone of treatment for HR + /HER2- MBC. The introduction of novel endocrine-based therapies has changed the landscape of metastatic breast cancer care, with even more promising agents on the horizon. Given the co...
Samuel Ruder,Andres Ricaurte-Fajardo,Michael Sun et al.
Samuel Ruder et al.
Prostate-specific membrane antigen targeted radionuclide therapies (PSMA-TRT) such as 177Lu-PSMA-617 hold great promise in improving clinical outcomes at various stages of prostate cancer. The FDA approval of 177Lu-PSMA-617 represents a sig...